Reportedly, the FOS and FOSB genes activate and upregulate the IL-17 signaling pathway,39 which promotes the expression of the cancer-promoting gene CCL20.40 The activation of the IL-17 signaling pathway in non-pCR patients may explain their poor response to therapy. This evidence concerns the gene IL17A and cancer.